Literature DB >> 22040911

Ephs and ephrins in cancer: ephrin-A1 signalling.

Amanda Beauchamp1, Waldemar Debinski.   

Abstract

Ephrin-A1 and its primary receptor, EphA2, are involved in numerous physiological processes and have been intensely studied for their roles in malignancy. Ephrin-Eph signalling is complex on its own and is also cell-type dependent, making elucidation of the exact role of ephrin-A1 in neoplasia challenging. Multiple oncogenic signalling pathways, such as MAP/ERK and PI3K are affected by ephrin-A1, and in some cases evidence suggests the promotion of a specific pathway in one cell or cancer type and inhibition of the same pathway in another type of cell or cancer. Ephrin-A1 also plays an integral role in angiogenesis and tumor neovascularization. Until recently, studies investigating ephrins focused on the ligands as GPI-anchored proteins that required membrane anchoring or artificial clustering for Eph receptor activation. However, recent studies have demonstrated a functional role for soluble, monomeric ephrin-A1. This review will focus on various forms of ephrin-A1-specific signalling in human malignancy.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22040911      PMCID: PMC3288643          DOI: 10.1016/j.semcdb.2011.10.019

Source DB:  PubMed          Journal:  Semin Cell Dev Biol        ISSN: 1084-9521            Impact factor:   7.727


  90 in total

1.  Tumor necrosis factor-alpha induction of endothelial ephrin A1 expression is mediated by a p38 MAPK- and SAPK/JNK-dependent but nuclear factor-kappa B-independent mechanism.

Authors:  N Cheng; J Chen
Journal:  J Biol Chem       Date:  2001-02-02       Impact factor: 5.157

2.  Hypoxia up-regulates expression of Eph receptors and ephrins in mouse skin.

Authors:  Meri M Vihanto; Jan Plock; Dominique Erni; Brigitte M Frey; Felix J Frey; Uyen Huynh-Do
Journal:  FASEB J       Date:  2005-08-04       Impact factor: 5.191

3.  A conditional feedback loop regulates Ras activity through EphA2.

Authors:  Madhu Macrae; Richard M Neve; Pablo Rodriguez-Viciana; Christopher Haqq; Jennifer Yeh; Chira Chen; Joe W Gray; Frank McCormick
Journal:  Cancer Cell       Date:  2005-08       Impact factor: 31.743

4.  Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma.

Authors:  Christopher J Herrem; Tomohide Tatsumi; Kathleen S Olson; Keisuke Shirai; James H Finke; Ronald M Bukowski; Ming Zhou; Amy L Richmond; Ithaar Derweesh; Michael S Kinch; Walter J Storkus
Journal:  Clin Cancer Res       Date:  2005-01-01       Impact factor: 12.531

5.  Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior.

Authors:  Kelly Carles-Kinch; Katherine E Kilpatrick; Jane C Stewart; Michael S Kinch
Journal:  Cancer Res       Date:  2002-05-15       Impact factor: 12.701

6.  EphrinA1 inactivates integrin-mediated vascular smooth muscle cell spreading via the Rac/PAK pathway.

Authors:  Christophe Deroanne; Valérie Vouret-Craviari; Bingcheng Wang; Jacques Pouysségur
Journal:  J Cell Sci       Date:  2003-04-01       Impact factor: 5.285

7.  Ephrin-A1 is expressed at sites of vascular development in the mouse.

Authors:  J L McBride; J C Ruiz
Journal:  Mech Dev       Date:  1998-10       Impact factor: 1.882

8.  EFNA1 ligand and its receptor EphA2: potential biomarkers for hepatocellular carcinoma.

Authors:  Xiang-Dan Cui; Mi-Jin Lee; Goung-Ran Yu; In-Hee Kim; Hee-Chul Yu; Eun-Young Song; Dae-Ghon Kim
Journal:  Int J Cancer       Date:  2010-02-15       Impact factor: 7.396

Review 9.  The role of Eph receptors and ephrin ligands in colorectal cancer.

Authors:  Nirmitha I Herath; Andrew W Boyd
Journal:  Int J Cancer       Date:  2010-05-01       Impact factor: 7.396

10.  Expressions of EphA2 and EphrinA-1 in early squamous cell cervical carcinomas and their relation to prognosis.

Authors:  Ruth Holm; Gregg Van de Putte; Zhenhe Suo; A Kathrine Lie; Gunnar B Kristensen
Journal:  Int J Med Sci       Date:  2008-06-05       Impact factor: 3.738

View more
  41 in total

1.  Immunohistochemical demonstration of EphA2 processing by MT1-MMP in invasive cutaneous squamous cell carcinoma.

Authors:  Ryoko Tatsukawa; Kaori Koga; Mikiko Aoki; Naohiko Koshikawa; Shinichi Imafuku; Juichiro Nakayama; Kazuki Nabeshima
Journal:  Virchows Arch       Date:  2016-04-07       Impact factor: 4.064

2.  Transactivation of the receptor-tyrosine kinase ephrin receptor A2 is required for the low molecular weight hyaluronan-mediated angiogenesis that is implicated in tumor progression.

Authors:  Frances E Lennon; Tamara Mirzapoiazova; Nurbek Mambetsariev; Bolot Mambetsariev; Ravi Salgia; Patrick A Singleton
Journal:  J Biol Chem       Date:  2014-07-14       Impact factor: 5.157

3.  Tissue Engineering of Axially Vascularized Soft-Tissue Flaps with a Poly-(ɛ-Caprolactone) Nanofiber-Hydrogel Composite.

Authors:  Dominic Henn; Kellen Chen; Katharina Fischer; Annika Rauh; Janos A Barrera; Yoo-Jin Kim; Russell A Martin; Matthias Hannig; Patricia Niedoba; Sashank K Reddy; Hai-Quan Mao; Ulrich Kneser; Geoffrey C Gurtner; Justin M Sacks; Volker J Schmidt
Journal:  Adv Wound Care (New Rochelle)       Date:  2020-06-10       Impact factor: 4.730

4.  Structural and functional characterization of monomeric EphrinA1 binding site to EphA2 receptor.

Authors:  Carla M Lema Tomé; Enzo Palma; Sara Ferluga; W Todd Lowther; Roy Hantgan; Jill Wykosky; Waldemar Debinski
Journal:  J Biol Chem       Date:  2012-02-23       Impact factor: 5.157

5.  Advances in malignant pleural mesothelioma therapy: targeting EphA2 a novel approach.

Authors:  Najmunnisa Nasreen; Nazli Khodayari; Kamal A Mohammed
Journal:  Am J Cancer Res       Date:  2012-02-15       Impact factor: 6.166

6.  EphA2 Expression Regulates Inflammation and Fibroproliferative Remodeling in Atherosclerosis.

Authors:  Alexandra C Finney; Steven D Funk; Jonette M Green; Arif Yurdagul; Mohammad Atif Rana; Rebecca Pistorius; Miriam Henry; Andrew Yurochko; Christopher B Pattillo; James G Traylor; Jin Chen; Matthew D Woolard; Christopher G Kevil; A Wayne Orr
Journal:  Circulation       Date:  2017-05-09       Impact factor: 29.690

7.  The receptor tyrosine kinase EphA2 is a direct target gene of hypermethylated in cancer 1 (HIC1).

Authors:  Bénédicte Foveau; Gaylor Boulay; Sébastien Pinte; Capucine Van Rechem; Brian R Rood; Dominique Leprince
Journal:  J Biol Chem       Date:  2011-12-19       Impact factor: 5.157

8.  EphrinA1 is released in three forms from cancer cells by matrix metalloproteases.

Authors:  Amanda Beauchamp; Mark O Lively; Akiva Mintz; Denise Gibo; Jill Wykosky; Waldemar Debinski
Journal:  Mol Cell Biol       Date:  2012-06-11       Impact factor: 4.272

9.  Proteolysis of EphA2 Converts It from a Tumor Suppressor to an Oncoprotein.

Authors:  Naohiko Koshikawa; Daisuke Hoshino; Hiroaki Taniguchi; Tomoko Minegishi; Taizo Tomari; Sung-Ouk Nam; Mikiko Aoki; Takayuki Sueta; Takashi Nakagawa; Shingo Miyamoto; Kazuki Nabeshima; Alissa M Weaver; Motoharu Seiki
Journal:  Cancer Res       Date:  2015-06-30       Impact factor: 12.701

10.  Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor.

Authors:  Matteo Incerti; Massimiliano Tognolini; Simonetta Russo; Daniele Pala; Carmine Giorgio; Iftiin Hassan-Mohamed; Roberta Noberini; Elena B Pasquale; Paola Vicini; Silvia Piersanti; Silvia Rivara; Elisabetta Barocelli; Marco Mor; Alessio Lodola
Journal:  J Med Chem       Date:  2013-03-22       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.